Finanzen von Catheter Precision Inc (VTAK)VTAKCatheter Precision Inc

Evaluating the bottom line, Catheter Precision Inc maintains a gross margin of 9.62%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -388.13%, while the net margin is -324.44%. These profitability ratios, combined with a Return on Equity (ROE) of -111.90%, provide a clear picture of how effectively VTAK converts its operational activities into shareholder value.

In the context of the broader market, VTAK competes directly with industry leaders such as XAIR and BRTX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, VTAK's gross margin of 9.62% stands against XAIR's 12.73% and BRTX's 68.13%. Such benchmarking helps identify whether Catheter Precision Inc is trading at a premium or discount relative to its financial performance.

The latest quarterly revenue for VTAK was $1.02 million, showing growth compared to previous quarters, but the net income remains negative, with a loss of $2.56 million in the most recent quarter. The gross margin has significantly decreased to 9.62%, down from over 90% in earlier quarters, indicating potential issues with cost management or pricing.